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SUMMARY
BACKGROUND—Excess alcohol use among tuberculosis (TB) patients complicates TB control 
strategies.
OBJECTIVES—To characterize the role of excess alcohol use in TB control, we describe the 
epidemiology of excess alcohol use and TB in the United States among those aged ≥15 years.
DESIGN—Using data reported to the National Tuberculosis Surveillance System, 1997–2012, we 
examined associations between excess alcohol use and TB treatment outcomes and markers for 
increased transmission (involvement in a local genotype cluster of cases) using multivariate 
logistic regression. We used Cox proportional hazards regression analysis to examine the 
relationship between excess alcohol use and the rate of conversion from positive to negative in 
sputum culture results.
RESULTS—Excess alcohol use was documented for 31 207 (15.1%) of 207 307 patients. 
Prevalence of excess alcohol use was greater among male patients (20.6%) and US-born patients 
(24.6%). Excess alcohol use was associated with a positive sputum smear result (aOR 1.23, 
95%CI 1.18–1.28) and death during treatment (vs. completion of treatment) (aOR 1.16, 95%CI 
1.10–1.22). The rate of culture conversion was higher among patients without excess alcohol use 
(adjusted hazard ratio 1.20, 95%CI 1.18–1.23).
CONCLUSIONS—Excess alcohol use was common among patients with TB, and was associated 
with TB transmission, lower rates of sputum culture conversion, and greater mortality.
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Tuberculosis (TB) incidence continues to decrease in the United States, with fewer than 10 
000 cases reported nationwide in 2012;1 however, excess alcohol use remains common. 
Correspondence to: Tyson Volkmann, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, MS-E-10, 
1600 Clifton Road NE, Atlanta, GA 30329, USA. Tel: (+1) 404 639 6469. Fax: (+1) 404 718 8308. xdh4@cdc.gov. 
Conflicts of interest: none declared.
HHS Public Access
Author manuscript
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 March 18.
Published in final edited form as:













Excess alcohol use accounted for an estimated 88 000 deaths in the United States each year 
during 2006–2010,2 and an estimated US$224 billion in economic costs in 2006.3 Excessive 
alcohol use includes binge drinking, exceeding weekly limits, and any use by pregnant 
women or persons aged <21 years. In 2011, binge drinking was reported by 18.3% of US 
adults, who reported doing so an average of four times a month and consuming an average 
of 8 drinks per occasion.4 Substance use (including excess alcohol use) among patients with 
TB remains highly prevalent in the United States5 and abroad.6
Alcohol use might be responsible for a large proportion of TB program burden,7 which is 
represented by a strong association between excessive alcohol use and TB.8 This association 
may be explained by the progression of latent tuberculous infection to TB disease due to 
decreased immune system function among excess alcohol users,9 and exacerbated by other 
associated factors such as homelessness10 and smoking.11 Studies have shown excess 
alcohol use to be associated with a positive acid-fast bacilli (AFB) sputum smear 
microscopy result,12 delay in TB diagnosis,13 anti-tuberculosis treatment,13 and poor TB 
treatment outcomes.14 Excess alcohol use is also associated with an increased risk of 
belonging to a localized TB genotype cluster,15,16 suggesting an association between alcohol 
use and recent TB transmission.
Despite the high prevalence of excess alcohol use described among TB patients, and the 
associated comorbidity and mortality, no recent nationwide analysis examining the 
prevalence of excess alcohol use and potential associations has been published. We 
investigated the prevalence of excess alcohol use among TB patients reported in the United 
States from 1997 to 2012. We assessed the association of excess alcohol use with markers 
for TB transmission and with treatment outcomes, while adjusting for the effects of other 
demographic and clinical characteristic variables routinely reported in US TB surveillance. 
We also assessed whether time to sputum culture conversion was associated with excess 
alcohol use among patients with pulmonary TB.
STUDY POPULATION AND METHODS
Data collection
We used data from the National Tuberculosis Surveillance System (NTSS), which contains 
demographic and clinical information for each reported TB case in the United States and the 
District of Columbia. Incident cases of TB disease in persons aged ≥15 years reported to the 
NTSS for 1997–2012 were selected for this analysis. Molecular genotype data of 
Mycobacterium tuberculosis complex isolates were linked to NTSS case-based records, as 
described elsewhere.17 For analyses involving genotyping data, incident culture-positive TB 
cases in the NTSS for 2009–2012 with matched genotype results were used. Similar to a 
previous analysis, a genotype cluster was defined as two or more cases of TB with the same 
genotype matched using 24-locus mycobacterial interspersed repetitive unit (MIRU) and 
spacer oligonucleotide typing, and reported in the same county and state.18
As data for the NTSS are collected as part of routine public health practice and not for the 
purposes of human subjects’ research, the study proposal was reviewed by the National 
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers of Disease Control 
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and Prevention, Atlanta, GA, and it was determined that institutional review board approval 
was not required.
Excess alcohol use is defined as having used alcohol in excess within the past 12 months.19 
Information for this variable is either self-reported or medically documented. If excess 
alcohol use is not self-reported by the patient, the health provider or TB controller is tasked 
with determining whether excess alcohol use occurs. This determination can be made over 
the course of numerous appointments. Homelessness, injection drug use, and non-injection 
drug use are defined as any period of self-reported behavior in the 12 months before the 
diagnosis of TB disease. Poor treatment outcomes were defined as being lost to follow-up, 
not complying with or refusing treatment, among those for whom treatment was stopped vs. 
treatment completion. Patients who died during treatment or whose completion status was 
unknown or missing were not included in the analysis of poor treatment outcomes. To be 
included in the variable ‘pulmonary cavity diagnosed by X-ray’, individuals also had to have 
documentation of an abnormal X-ray. Only those with a positive sputum culture result and 
initial drug susceptibility testing results were considered for analyses of drug resistance. 
Patients with documented human immunodeficiency virus (HIV) infection were coded as 
‘known positive’, whereas patients with negative or unknown status were coded as ‘other’.
Statistical analysis
Prevalence of excess alcohol use among TB patients in the United States—
Trends in the prevalence of excess alcohol use were assessed using a Mantel-Haenszel 
extension of the χ2 test for trend.20 The prevalence of excess alcohol use was also stratified 
by state and categorized by quartile.
Bivariate associations between excess alcohol use, select characteristics and 
TB outcomes—Bivariate associations between excess alcohol use and demographic and 
clinical variables were assessed using crude odds ratios (ORs) and 95% confidence intervals 
(CIs).
Multivariate associations between excess alcohol use and TB outcomes—
Multivariate logistic regression analysis was conducted to assess the association of excess 
alcohol use and select variables. Adjusted odds ratios (aORs) significant at the 95% 
confidence level are displayed. We did not include the multidrug-resistant and extensively 
drug-resistant variables in multivariate analysis due to large amounts of missing data in 
these variables. Analyses of genotype data were restricted to 2009–2012, as 24-locus MIRU 
data were only available for 2009 onward.
Analyses of time to sputum culture conversion—We conducted a Kaplan-Meier 
analysis to assess whether time to and rate of sputum culture conversion differed between 
patients with and those without documented excess alcohol use. Time to conversion was 
defined as the number of days between the start of treatment and the date of the first 
consistently negative result from sputum culture. Analysis was limited to patients with 
pulmonary TB who were culture-positive; had confirmed susceptibility to isoniazid, 
rifampin, and ethambutol; had no known resistance to pyrazinamide; were started on a 
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standard four-drug regimen;21 had documentation of a negative sputum culture result; had a 
temporally valid documentation of date of sputum culture conversion; and, for those who 
culture converted, before stopping treatment and within 4 months (standard time after which 
treatment is considered failed);22 and were reported as either ‘yes’ or ‘no’ to the excess 
alcohol use question.
We plotted time to sputum culture conversion within 4 months of the start of anti-
tuberculosis treatment by excess alcohol use using Kaplan-Meier curves. Differences were 
assessed using log-rank statistics, while hazard ratios (HRs) and 95%CIs for rate of culture 
conversion were calculated using Cox proportional hazard regression analyses to obtain 
adjusted hazard ratios (aHRs). The adjusted analysis controlled for age group, sex, race/
ethnicity, and homelessness.
RESULTS
Prevalence of excess alcohol use among confirmed TB patients in the United States
During the study period, 207 307 TB cases were reported among persons aged ≥15 years 
(Figure 1). Of these, excess alcohol use was documented for 31 207 (15.1%; yearly range 
12.4–17.3) (data not shown); 22 733 (72.8%) were born in the United States (US-born) and 
8474 (28.2%) outside the United States (foreign-born). For 1997–2012, the prevalence of 
excess alcohol use differed significantly between US-born and foreign-born patients (24.3%, 
range 22.8–25.6 vs. 7.5%, range 6.5–8.4; P < 0.001; Figure 1). The prevalence of excess 
alcohol use for 1997–2012 decreased significantly, from 25.3% to 23.1%, among US-born 
persons (P < 0.001), but did not change significantly among foreign-born persons (P = 
0.842). Beginning in 2005 for US-born (P = 0.429) and in 2008 for all patients with TB (P = 
0.051), there was no significant change in excess alcohol use prevalence. Excess alcohol use 
prevalence among TB patients varied by state by a factor of nearly nine, ranging from 5.1% 
in Rhode Island to 44.5% in Montana (Figure 2).
Bivariate associations between excess alcohol use and select characteristics 
and TB outcomes—Excess alcohol use was more common among males than females, 
among patients aged 45–64 years than among other age groups, among American Indians or 
Alaska Natives than other races, and among US-born than foreign-born patients (Table 1). 
TB patients with excess alcohol use were more likely to be homeless and to have used 
injection or non-injection drugs during the past year. Those with excess alcohol use were 
also more likely to be HIV-positive.
Multivariate associations between excess alcohol use and TB outcomes—
Excess alcohol use was independently associated with positive AFB sputum smear 
microscopy results (aOR 1.23, 95%CI 1.18–1.28), pulmonary vs. extra-pulmonary site of 
disease (aOR 1.31, 95%CI 1.23–1.39), having a pulmonary cavity diagnosed on X-ray (aOR 
1.21, 95%CI 1.16–1.25), and genotype cluster involvement (aOR 1.36, 95%CI 1.23–1.50). 
With regard to measures of anti-tuberculosis treatment, excess alcohol use was associated 
with receiving directly observed therapy (DOT) vs. self-administered therapy (SAT) (aOR 
1.92, 95%CI 1.81–2.03). Compared with completion of treatment, rates of death (aOR 1.16, 
95%CI 1.10–1.22) or loss to follow-up (aOR 1.25, 95%CI 1.15–1.37) were significantly 
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higher in those with excess alcohol use (Table 1). A total of 67 patients (0.03%) had 
treatment outcome information missing and were excluded from further analyses. The 
proportion of patients with missing treatment outcome information and reported excess 
alcohol use was not significantly different from that observed among those with no reported 
excess alcohol use (P > 0.99).
Analyses of time to culture conversion—The proportion of patients with culture 
conversion was significantly lower for those who reported excess alcohol use (88.6%) than 
those who did not (92.3%, P < 0.001; Table 2). Analysis of time to culture conversion 
indicated a significant difference between median days to culture conversion for those for 
whom excess alcohol use was reported vs. those for whom it was not (54 days, interquartile 
range [IQR] 31–76 vs. 43 days, IQR 25–66; P = 0.001). After adjustment for race/ethnicity, 
age, sex, and homelessness, the rate of sputum culture conversion remained significantly 
higher for those without excess alcohol use (aHR 1.20, 95%CI 1.18–1.23). When the 
adjusted analysis was stratified by therapy, the rate of conversion among those without 
excess alcohol use was significantly higher for those treated with DOT (aHR 1.22, 95%CI 
1.19–1.25), but not for those who underwent SAT (aHR 1.11, 95%CI 0.99–1.25) (Figure 3).
DISCUSSION
Nearly one in six TB patients consumes alcohol in excess, and this behavior complicates TB 
control at every level. These findings echo research from abroad and from other US states 
and cities.5,6,23,24 The burden of alcohol and TB is distributed disproportionately in the 
United States, with 12 states reporting an overall prevalence of excess alcohol use among 
TB patients ranging between 19% and 44%. Among US-born patients with TB, the 
prevalence of excess alcohol use has been >20% each year since 1997, suggesting that 
excess alcohol use needs to be considered when addressing TB control in the United States. 
The prevalence of excess alcohol use among US-born patients with TB has remained steady 
since 2005 and among foreign-born patients with TB since 1997. While the prevalence of 
excess alcohol use among TB patients appears to be lower than that of binge drinking in the 
general population of the United States, it should be noted that these measures of alcohol use 
are not equivalent, and that the proportion of foreign-born TB patients in the United States is 
approaching 50%, among whom only 7.5% had excess alcohol use reported. This drives 
down the overall prevalence of excess alcohol use compared to that of the general 
population in the United States. As a common factor among patients with TB, excess 
alcohol use may represent a large portion of the morbidity and mortality associated with TB 
in the United States, and may be a marker for other factors that were not included in this 
analysis, including smoking and poverty.
This study has limitations. First, the variable ‘excess alcohol use’ collected in the NTSS and 
used in this study lacks a specific definition. The specificity of this variable could be 
increased by systematically implementing a reliable, valid use measure, such as the single-
question screen measure used by the National Institute on Alcohol Abuse and Alcoholism 
(National Institutes of Health, Bethesda, MD).25 However, the current, broad definition 
remains in place due to requests from TB programs that are striving to ensure that all 
patients with excess alcohol use are captured. Second, the reliability of self-reported or 
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medically documented data on excess alcohol use is unknown. As a potentially stigmatized 
behavior, it is probable that the prevalence of excess alcohol use is underreported. 
Importantly, our analysis was unable to analyze the potential confounding effects of 
smoking on the excess alcohol use/TB outcome association. Unfortunately, as the NTSS 
does not collect information on tobacco smoking, we were not able to perform an analysis 
that controlled for smoking.
Alcohol use is associated with the development of TB disease,8 probably due to impaired 
immune function.26 In addition, excess alcohol use among TB patients has been linked to 
TB transmission27 and adverse treatment outcomes.28 Our results are consistent with these 
findings, as excess alcohol use was associated with pulmonary vs. extra-pulmonary disease, 
a positive sputum smear result, having a diagnosed pulmonary cavity and being included in 
a local genotype cluster. Each of these factors can influence transmission, including 
clustering, which has been linked to recent transmission.29 Furthermore, excess alcohol use 
was associated with non-injection drug use and homelessness, both of which negatively 
impact our ability to control TB through the difficulty in locating contacts and ensuring 
treatment adherence.30,31
The odds of documented excess alcohol use were greater among those with poor treatment 
outcomes and for those who died vs. those who completed treatment. These findings support 
those from past studies that reported that patients who used alcohol in excess were more 
likely to experience adverse treatment outcomes.32,33 A recent study in India found that 
persons who consumed alcohol during treatment missed on average 18 (95%CI 13–22) more 
intensive phase doses than those who did not.34 A variety of factors probably account for 
poor treatment outcomes: TB patients who drink excessively may be less likely to have 
adequate social support, housing, and transportation to appointments for care, and may be 
unable to attend appointments for treatment due to factors related to substance use.35 
Furthermore, medication failure is possible due to immunosuppression36 and changes in 
pharmacokinetics8,37 caused by alcohol consumption. In the current study, among patients 
who culture converted within 4 months, those for whom excess alcohol use was not 
documented completed treatment more than a week sooner on average, demonstrating that 
patients who use alcohol in excess may be more likely to fail treatment and require 
additional resources from TB control programs.
Further complicating anti-tuberculosis treatment among TB patients who consume alcohol 
in excess is the additional hepatic damage caused by the metabolism of alcohol. The 
majority of anti-tuberculosis medications are processed in the liver,38 where additive 
hepatotoxic effects can occur.39 This outcome is more commonly found in those who 
consume alcohol in excess than in those who do not.40 For people who are known to be 
currently using alcohol in excess or have a history of alcohol abuse, the American Thoracic 
Society recommends treatment with fewer TB medications to reduce the hepatotoxic effects 
from the additive effects of excess alcohol use and anti-tuberculosis treatment.41 Cigarette 
smoking is more common among those who use excess alcohol than among those who do 
not, and is also associated with tuberculous infection and progression to TB disease.11 
Smoking might complicate anti-tuberculosis treatment through poor TB outcomes (e.g., 
relapse after treatment).42 The association between smoking and TB may also be responsible 
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for some of the effects observed between excess alcohol use and the outcomes in the current 
study.
In addition to being less likely to complete anti-tuberculosis treatment, a significantly higher 
proportion of those who used alcohol in excess were prescribed DOT than those who did not 
use alcohol in excess; those who consumed alcohol in excess were nearly twice as likely to 
receive DOT as SAT. As DOT requires active supervision by a health care worker, the cost 
in terms of human resources is higher for each TB patient treated with DOT.43 Despite this 
extra attention from the system, TB patients who used alcohol in excess were still less likely 
to complete treatment than those who did not. After adjusting for race/ethnicity, sex, age, 
and homelessness, the rate of culture conversion among those who did not use alcohol in 
excess was significantly greater. The conversion rate maintained statistical significance after 
stratification among those who did not use alcohol in excess who were receiving DOT, 
which indicates that, even with supervised treatment, those who used alcohol in excess take 
longer to cure. The increased treatment time under DOT ostensibly means that those who 
use alcohol in excess may require an even larger proportion of resources during anti-
tuberculosis treatment than those who do not.
One strategy that may provide an opportunity for clinical intervention is alcohol screening 
and brief intervention. Since 2004, the US Preventive Services Task Force (Rockville, MD) 
has recommended alcohol screening and behavioral counseling (also known as alcohol 
screening and brief intervention [ASBI]) for all adults in primary care to address excessive 
alcohol use. This review of evidence indicated that brief (6–15 min) intervention sessions 
were effective in significantly reducing weekly alcohol consumption (by 3.6 fewer drinks/
week for adults) and binge level episodes (reported by 12% fewer participants) and 
increasing adherence to recommended drinking limits (achieved by 11% more 
participants).44 Furthermore, the effects can last for years and show improvement in health 
care utilization outcomes, including fewer hospital days and lower costs.44
Another strategy consists of an integrated approach to concurrently treating both excessive 
alcohol use and TB. This is an approach that represents a dual-purpose opportunity. While 
very few programs appear to have utilized such an approach to co-treating excess alcohol 
use and TB,45 and few current programs with TB and alcohol treatment exist, this model is 
fairly well established in the literature on injection drug use in populations at high risk for 
transmission of HIV-TB.46 A similar model might utilize a holistic approach that addresses 
a variety of factors, such as the concomitant social (e.g., homelessness), psychological (e.g., 
unmet mental health needs), physiological (e.g., alcohol dependence), and physical health 
issues (e.g., TB) that are simultaneously affecting a disproportionately large number of TB 
persons. This strategy presents an opportunity for the health system to manage multiple 
related issues, which could result in an overall cost savings to the system and respond to 
calls in the literature for integrative approaches to co-treating infectious disease and 
substance use disorders.46–49
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Proportion of excess alcohol use among confirmed TB cases aged ≥15 years reported to the 
National TB Surveillance System, United States, 1997–2012 (n = 207 307).* Trend P < 
0.0001.
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Excess alcohol use in previous year among persons aged ≥15 years with reported 
tuberculosis diagnosis, United States, 1997–2012.
Volkmann et al. Page 12














Time (in days) from start of treatment to conversion to negative sputum culture by excess 
alcohol use vs. no excess alcohol use in past year in individuals treated with A) self-
administered therapy and B) directly observed therapy, among persons reported with TB, 
United States, 1997–2012. (Horizontal line indicates the median time point and vertical lines 
indicate the median time point to culture conversion.)
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Table 1
Factors associated with excess alcohol use among persons aged ≥15 years reported with a TB diagnosis, 
United States, 1997–2012 (n = 207 307)
Variable n (%)*
Subjects with documented 
excess alcohol use n (%)* Crude OR (95%CI) Adjusted OR (95%CI)†
Demographic characteristics and behaviors
 Male sex 128 713 (62.10) 27 051 (20.62) 4.31 (4.17–4.45) 3.34 (3.21–3.47
 Age group, years
  15–24 22 559 (10.88) 1 317 (5.84) 1.0 (reference) 1.0 (reference)
  25–44 74 706 (36.04) 12 117 (16.22) 3.12 (2.95–3.31) 2.82 (2.63–3.02)
  45–64 63 789 (30.77) 14 920 (23.39) 4.92 (4.65–5.214) 4.094 (3.82–4.389)
  ≥65 46 253 (22.31) 2 604 (5.63) 0.96 (0.90–1.03) 1.21 (1.12–1.32)
 Racial/ethnic group
  White 41 959 (20.30) 7 947 (18.94) 1.0 (reference) 1.0 (reference)
  American Indian 2 544 (1.23) 1 040 (40.88) 2.96 (2.72–3.21) 2.73 (2.45–3.03)
  Asian 49 922 (24.15) 1 662 (3.33) 0.15 (0.14–0.16) 0.49 (0.45–0.52)
  Black 58 149 (28.13) 12 507 (21.51) 1.17 (1.14–1.21) 0.97 (0.94–1.01)
  Hispanic 52 622 (25.46) 7 919 (15.05) 0.76 (0.73–0.78) 1.35 (1.29–1.43)
  Multiple 676 (0.33) 49 (7.32) 0.34 (0.25–0.45) 0.80 (0.56–1.14)
  Hawaiian/Pacific Islander 829 (0.40) 72 (8.68) 0.41 (0.36–0.46) 0.97 (0.72–1.32)
 US born vs. foreign born 92 489 (44.69) 22 733 (24.58) 3.95 (3.85–4.06) 2.51 (2.40–2.63)
 Homeless during last year 12 762 (6.21) 7 186 (56.31) 9.27 (8.93–9.62) 2.83 (2.70–2.97)
 Injection drug use, past year 4 621 (2.25) 2 699 (58.41) 9.03 (8.52–9.57) 1.80 (1.67–1.95)
 Non-injection drug use, past year 15 956 (7.78) 9 438 (59.15) 12.00 (11.59–12.41) 5.29 (5.05–5.53)
Clinical and epidemiological characteristics
 Known HIV-positive 17 600 (8.49) 4 247 (24.13) 1.77 (1.70–1.84) 1.40 (1.34–1.48)
 Sputum smear result
  Negative 85 789 (44.13) 10 664 (12.43) 1.0 (reference) 1.0 (reference)
  Positive 76 156 (39.17) 16 297 (21.40) 1.92 (1.87–1.97) 1.23 (1.18–1.28)
  Not tested 32 477 (16.70) 2 137 (6.58) 0.50 (0.47–0.52) 1.06 (0.91–1.23)
 Sputum culture result
  Negative 44 080 (22.80) 4 544 (10.31) 1.0 (reference) 1.0 (reference)
  Positive 115 929 (59.95) 22 358 (19.31) 2.08 (2.01–2.15) 1.36 (1.29–1.43)
  Not tested 33 360 (17.25) 2 135 (6.40) 0.60 (0.57–0.63) 0.85 (0.73–0.99)
 Disease site
  Extra-pulmonary 41 367 (19.96) 2 622 (6.34) 1.0 (reference) 1.0 (reference)
  Pulmonary 147 540 (71.20) 25 568 (17.33) 3.10 (2.97–3.23) 1.31 (1.23–1.39)
  Both 18 316 (8.84) 2 744 (14.98) 2.60 (2.46–2.75) 1.20 (1.11–1.29)
 Pulmonary cavity diagnosed by X-ray 47 160 (27.69) 10 238 (21.71) 1.55 (1.51–1.59) 1.21 (1.16–1.25)
 Cluster involvement‡ 7 209 (23.60) 1 010 (14.01)† 2.52 (2.35–2.70) 1.36 (1.23–1.50)
 First-line drug resistance 16 893 (8.15) 2 083 (12.33) 0.79 (0.75–0.82) 0.90 (0.85–0.95)
 Multidrug-resistant TB§ 1 558 (1.35%) 164 (10.55) 0.563 (0.48–0.66) —
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Variable n (%)*
Subjects with documented 
excess alcohol use n (%)* Crude OR (95%CI) Adjusted OR (95%CI)†
 Extensively drug-resistant TB§ 31 (0.36) 4 (12.90) 1.40 (0.57–3.42) —
 Directly observed therapy
  No (self-administered) 32 694 (16.79) 2 056 (6.29) 1.0 (reference) 1.0 (reference)
  Yes 106 140 (54.49) 18 829 (17.74) 3.21 (3.06–3.37) 1.92 (1.81–2.03)
  Both 55 941 (28.72) 8 251 (14.75) 2.58 (2.45–2.71) 1.82 (1.71–1.93)
 Poor treatment outcomes 5 929 (3.41) 1 309 (22.09) 1.64 (1.54–1.75) 1.55 (1.04–2.31)
 Reason for stopping treatment
  Completed 167 985 (86.92) 24 576 (14.63) 1.0 (reference) 1.0 (reference)
  Died 15 057 (7.79) 2 569 (17.06) 1.20 (1.15–1.25) 1.16 (1.10–1.22)
  Lost 4 678 (2.42) 1 100 (23.51) 1.79 (1.68–1.92) 1.25 (1.15–1.37)
  Moved 4 189 (2.17) 547 (13.05) 0.88 (0.80–0.96) 1.11 (0.99–1.24)
  Refused treatment 1 251 (0.65) 209 (16.73) 1.17 (1.01–1.36) 1.35 (1.11–1.62)
*
Numbers may not reflect 100% of data due to missing data.
†
Variables with adjusted ORs were adjusted for all other variables in the table except for multidrug resistance, extensive drug resistance, and 
cluster involvement.
‡
Variables that had >10% missing data were not included in the adjusted analysis.
§
Data from 2009–2012 only.
TB = tuberculosis; OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus.
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